Related Experiment Video
Updated: Apr 29, 2026
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
A single slide multiplex assay for the evaluation of classical Hodgkin lymphoma
Denise Hollman-Hewgley1, Michael Lazare, Alex Bordwell
1*Clarient Diagnostic Services Inc., a GE Healthcare Company †Clarient Pathology Services Inc., Aliso Viejo, CA.
Insights
A new hyperplexing technology, MultiOmyx™, aids in diagnosing classical Hodgkin lymphoma, especially in challenging cases. This advanced multiplexing shows high accuracy, improving upon traditional methods for hematopathology diagnosis.
Area of Science:
- Hematopathology
- Immunohistochemistry
- Diagnostic Pathology
Background:
- Classical Hodgkin lymphoma diagnosis can be challenging in a subset of cases.
- Traditional diagnostic methods like hematoxylin and eosin and standard immunohistochemistry may have limitations.
Purpose of the Study:
- To evaluate the utility of a novel hyperplexing technology, MultiOmyx™, for diagnosing classical Hodgkin lymphoma.
- To assess the sensitivity, specificity, and precision of MultiOmyx™ compared to conventional techniques.
Main Methods:
- Utilized MultiOmyx™ technology to stain single tissue sections with over 60 antibodies.
- Included antibodies such as CD30, CD15, PAX-5, CD20, CD79a, CD45, BOB.1, OCT-2, and CD3 in the multiplexing protocol.
- Compared results with routine hematoxylin and eosin and immunohistochemical assessments.
Main Results:
- The MultiOmyx™ technology demonstrated high sensitivity, specificity, and precision.
- Concordance was observed in 54 out of 56 cases when compared to traditional methods.
- Two discordant cases highlighted the potential of multiplexed immunofluorescence to enhance diagnostic accuracy.
Conclusions:
- MultiOmyx™ is a practical technology for routine diagnosis of classical Hodgkin lymphoma.
- This multiplexing approach is particularly beneficial for limited sample sizes, rare cell populations, or morphologically difficult CD30-positive lymphomas.
- The technology holds potential for broader applications in research and diagnostic pathology.
Abstract:
Classical Hodgkin lymphoma can be diagnosed with confidence in the majority of cases, but there is a significant subset that remains a diagnostic challenge. The authors have investigated the utility of a novel hyperplexing technology, MultiOmyx™, which may be applied to stain with >60 antibodies on single tissue sections from formalin-fixed paraffin-embedded tissue as an aid to the diagnosis of classical Hodgkin lymphoma. The multiplexing protocol included CD30, CD15, PAX-5, CD20, CD79a, CD45, BOB.1, OCT-2, and CD3 antibodies. The technology showed a high degree of sensitivity, specificity, and precision. Comparison studies with routine hematoxylin and eosin and immunohistochemical assessment of hematopathology cases in which classical Hodgkin lymphoma was included in the differential diagnosis showed concordance in 54 of 56 cases, with the 2 discordant cases illustrating the potential of this multiplexed immunofluorescence technology to improve on traditional immunohistochemistry for classical Hodgkin lymphoma diagnosis. This technology is practical for routine diagnosis and may be particularly useful in cases in which the sample size is limited, few Hodgkin-like cells are present, or in CD30-positive lymphoma cases with difficult morphology. MultiOmyx may potentially benefit other areas of research and diagnostic pathology.
